Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases. Backed by 5AM Ventures.
About the role
We are seeking a dynamic Clinical Pharmacology Consultant who will bring extensive expertise in clinical pharmacology to our clinical stage programs. The ideal candidate will have a strong background in study design within the biotechnology or pharmaceutical industry and be passionate about translating science into approved and accessible medicines. You will report directly to the Head of Clinical Pharmacology and partner closely with various functions of our growing organization. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- MS 8+ years or Ph.D. and 3 + years in pharmaceutical sciences, pharmacology, pharmacometrics, pharmacokinetics, or related discipline or Pharm.D. or M.D. with relevant experience
- Publication record with a demonstrated technical exposure to early exploratory trials through Phase 2/3 programs preferred
- Experience using Phoenix WinNonlin, R, NONMEM, MATLAB, or other pharmacokinetic and modeling software
- Compartmental PK/PD modeling experience is a plus
- Strong mathematical model development and analytical skills
More about this role
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex...
Browse similar: Startup jobs · Boston